Unicycive Therapeutics, Inc..
Unicycive Theraputics (Nasdaq: UNCY) is a clinical-stage biotechnology company focused on developing kidney medications
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
Earlier this month
Gone quiet
No new reports in 90+ days-
Brookline Capital Markets lifted EPS estimates for Unicycive Therapeutics, Inc. on July 2, 2026.Some support3 reports
-
Shalabh Gupta became CEO of Unicycive Therapeutics, Inc. on July 7, 2025.Speculative1 report
-
Unicycive Therapeutics received orphan drug designation for UNI-494 and its treatment was reviewed by the FDA.Some support5 reports
No events began in the chosen period. Widen it, or reset.
Around Unicycive Therapeutics, Inc. this week
News at the entities that move Unicycive Therapeutics, Inc. most-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves Unicycive Therapeutics, Inc.
-
Nasdaq StructuralNeonode was listed on the Nasdaq stock exchange today.Moves Unicycive Therapeutics, Inc.
-
Benchmark TransactionalBenchmark lifted its price objective and gave a buy rating for Amazon.com.Moves Unicycive Therapeutics, Inc.
-
MarketBeat Mentioned togetherMarketBeat reported analyst recommendations for Broadwind Energy and LiqTech International, noting their volatility compared to the S&P 500.Moves Unicycive Therapeutics, Inc.
-
company Shared contextSilvercorp Metals Inc. is investigating potential claims on behalf of purchasers.Moves Unicycive Therapeutics, Inc.
-
LinkedIn Shared contextTzelios used a LinkedIn profile associated with Douglas Elliman.Moves Unicycive Therapeutics, Inc.
Connections
The 14 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Unicycive Therapeutics is under formal drug development review by the FDA, which has issued multiple Complete Response Letters regarding compliance and manufacturing deficiencies.
-
Shalabh Gupta Structural
Shalabh Gupta serves as the Chief Executive Officer and holds a 5.0% ownership stake in Unicycive Therapeutics, Inc.
-
Nasdaq Structural
Unicycive Therapeutics is formally listed and trades on the Nasdaq stock exchange.
-
John Townsend Structural
John Townsend served as the Chief Financial Officer of Unicycive Therapeutics, Inc.
-
Benchmark Transactional
Benchmark provides financial research reports and price objectives regarding Unicycive's shares.
-
LinkedIn Shared context
Unicycive Therapeutics utilizes LinkedIn as a platform for professional presence, investor outreach, and public communication.
-
DGF Operational
Unicycive Therapeutics is actively developing treatments aimed at preventing DGF.
-
National Kidney Foundation Mentioned together
Unicycive Therapeutics presented clinical data at National Kidney Foundation meetings.
Show all 14 connections
-
MarketBeat Mentioned together
MarketBeat provides consensus rating data for Unicycive Therapeutics, Inc.
-
American Nephrology Nurses Association Mentioned together
Unicycive Therapeutics presented research data at the American Nephrology Nurses Association symposium.
-
company Shared context
A lawsuit alleges that Unicycive made misleading statements regarding its status as a company.
-
Brookline Mentioned together
A financial entity named Brookline Capital Markets was mentioned in connection with the entities.
-
New York Shared context
Unicycive Therapeutics, Inc. is headquartered in New York.
-
ODD Mentioned together
No direct relationship between ODD and Unicycive Therapeutics, Inc. was observed in the provided evidence.